Skip to content

Biolivon publishes the science.

Biolivon
Not a peptide

SLU-PP-332

Also known as ERR agonist

A small-molecule ERR agonist described as an exercise mimetic.

PreclinicalMetabolic HealthMitochondrial Health
Human studies
0
Trials tracked
0
Preclinical
1
Safety signals
2
Last reviewed
11 Aug 2026
Reviewed by
Not yet reviewed

Not a peptide. Interesting early pharmacology in mice, reproducing some exercise-associated changes in muscle metabolism. There is no published human study of any kind — this is a laboratory compound being sold to consumers years ahead of any human data.

This dossier has not been reviewed yet. Our editorial board is not appointed. Every page is supposed to carry a named scientific and medical reviewer with declared conflicts, and until that is true this page has had no expert check — treat it accordingly. We would rather say so than print a name-shaped placeholder where a person should be.
SLU-PP-332 is not an approved medicine for human use in the jurisdictions listed below. This page summarises research. It is not a recommendation, and it contains no dosing or administration guidance. If you are considering anything described here, discuss it with a qualified clinician.
On this page

What it is

A synthetic small-molecule agonist of estrogen-related receptors, developed as a research tool for studying exercise-associated metabolic adaptation.

How it is proposed to work

ERR agonism upregulates genes involved in mitochondrial biogenesis and fatty acid oxidation — pathways that exercise also engages. 'Engages the same pathway' is a long way from 'substitutes for exercise', and the exercise-mimetic framing does most of the marketing work here.

Approved medical uses

None. SLU-PP-332 has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.

Human research

Each entry states what the study found and, separately, what it cannot show.

No adequate published human research. This absence is the reason for the evidence grade above — it is not a gap we can fill with animal data.

Preclinical research

Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.

  • Animal2023

    Mouse and muscle-cell study of ERR agonism and exercise endurance

    Finding. Administered to mice, it enhanced exercise endurance and increased type IIa oxidative skeletal muscle fibres, and induced an ERR-alpha-specific acute aerobic exercise genetic programme, with ERR-alpha activation critical for enhancing exercise endurance in mice. In a skeletal muscle cell line it increased mitochondrial function and cellular respiration.

    Limitation. The work reported here is in mice and in a skeletal muscle cell line. The reported outcomes are exercise endurance, type IIa oxidative skeletal muscle fibres, an ERR-alpha-specific acute aerobic exercise genetic programme, and mitochondrial function and cellular respiration in a skeletal muscle cell line. The compound is a pan agonist that targets all three ERRs, with the highest potency for ERR-alpha, and the authors present it as a chemical tool with pharmacokinetic properties sufficient for in vivo use. Three of the authors are stockholders in Myonid Therapeutics, Inc., which focuses on ERR based therapeutics.

Potential safety concerns

  • SeriousInsufficient

    No human data of any kind — no trials, no pharmacokinetics, no safety dataset. Nobody knows what it does in a person.

  • CautionInsufficient

    ERRs are highly expressed in cardiac tissue. A compound driving mitochondrial biogenesis systemically has cardiac implications that would need study before any reassurance is possible.

Known interactions and contraindication considerations

  • Entirely uncharacterised in humans.

This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.

Regulatory status

Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.

United States
FDA
Unapproved / investigational
as of 11 Aug 2026

A laboratory research compound. Not approved, and not a lawful dietary ingredient.

European Union
EMA
Unapproved / investigational
as of 11 Aug 2026

No marketing authorisation.

India
CDSCO
Unapproved / investigational
as of 11 Aug 2026

Not approved for human use. A first-time synthetically manufactured peptide falls under the new-drug pathway.

How it is being used

What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.

No community use documented for this compound yet. Absence here means our editorial team has not reviewed and verified a pattern — not that none exists.

Active clinical trials

No registered trials currently tracked for SLU-PP-332.

Search all tracked trials

What remains unknown

The questions that would change our assessment if they were answered.

  • Is it orally bioavailable in humans?
  • Do the mouse effects occur in a person, and at what cost elsewhere?
  • Does any exercise mimetic reproduce exercise's benefits, or only some markers of them?

References

  1. 1.Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS chemical biology. 2023.PMID 36988910doi

Editorial change history

When we change a grade or a regulatory note, we log it here rather than editing quietly.

  • Dossier created. No human study exists; none is implied.

Spotted something wrong? Tell us — we publish corrections.